Market Capitalization (Millions $) |
25 |
Shares
Outstanding (Millions) |
40 |
Employees |
27 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-34 |
Cash Flow (TTM) (Millions $) |
-11 |
Capital Exp. (TTM) (Millions $) |
0 |
Cognition Therapeutics Inc
Cognition Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative disorders, particularly Alzheimer's disease. The company aims to target the underlying mechanisms of cognitive decline and develop small molecule drugs that can restore cognitive function and slow disease progression. Cognition Therapeutics' innovative approach involves disrupting the interaction between a protein called Sigma-2 receptor and amyloid beta, a protein associated with Alzheimer's disease. By inhibiting this interaction, the company hopes to prevent the toxic effects of amyloid beta and potentially improve memory and cognition in affected individuals.
Company Address: 2500 Westchester Ave. Purchase 10577 NY
Company Phone Number: 481-2210 Stock Exchange / Ticker: NASDAQ CGTX
|